FAVOR III China试验5年随访:QFR指导PCI的长期疗效与安全性
FAVOR III China随机试验纳入冠脉中度狭窄患者,比较QFR指导与造影指导PCI。5年随访显示QFR组主要不良心脏事件复合终点低于造影组(17.5% vs 21.1%;HR 0.80;95%CI 0.69-0.92;P=0.002),获益主要在前2年累积,2年后两组无显著差异。
要点
- QFR指导PCI降低5年MACE风险,主要由心肌梗死和缺血驱动血运重建减少驱动。
- 全因死亡两组无差异,QFR指导策略长期安全性良好。
- 获益主要集中于术后前2年,2~5年两组事件率相似。
核心结论
- 与造影指导相比,QFR指导PCI策略改善5年临床结局,获益主要在前2年内实现。
研究设计与样本
- 多中心、随机、假手术对照FAVOR III China试验(NCT03656848),纳入至少1处造影中度狭窄(直径狭窄50%-90%)且血管直径≥2.5mm的患者,随机接受QFR指导(仅QFR≤0.80时行PCI)或造影指导策略,本文报告5年随访结果。
主要发现
- 5年时QFR组主要不良心脏事件复合终点低于造影组(17.5% vs 21.1%;HR 0.80;95%CI 0.69-0.92;P=0.002)。
- QFR组心肌梗死发生率较低(5.8% vs 9.0%;HR 0.63;95%CI 0.49-0.80;P<0.0001)。
- QFR组缺血驱动血运重建较少(9.6% vs 12.0%;HR 0.78;95%CI 0.64-0.95;P=0.02)。
- 全因死亡两组无差异。
- Landmark分析显示QFR获益主要在前2年累积(8.5% vs 12.5%;HR 0.66;95%CI 0.54-0.81;P<0.0001),2~5年两组结局相似(10.2% vs 11.2%;HR 0.90;95%CI 0.73-1.11;P=0.32;交互P=0.001)。
关键数值与推荐
- QFR指导组仅对QFR≤0.80的病变行PCI。
- 造影纳入标准为至少1处直径狭窄50%-90%的中度病变,参考血管直径≥2.5mm。
临床怎么用
- 对冠脉造影显示中度狭窄(50%-90%)且血管直径≥2.5mm的患者,可采用QFR指导PCI决策,以降低远期心肌梗死和缺血驱动血运重建风险。
- QFR指导的临床获益主要出现在术后前2年,长期随访仍需关注2年后的二级预防和风险因素管理。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The multicenter, randomized, sham-controlled FAVOR III China trial (Comparison of Quantitative Flow Ratio-Guided and Angiography-Guided Percutaneous Intervention in Patients with Coronary Artery Disease) demonstrated that quantitative flow ratio (QFR)-guided percutaneous coronary intervention (PCI) resulted in better outcomes compared with angiographic guidance at 1-year and 2-year follow-up. Whether these benefits are sustained over long-term follow-up remains uncertain. OBJECTIVES: The purpose of this study was to evaluate the long-term effectiveness and safety of a QFR-guided PCI strategy compared with angiography-guided PCI at 5 years. METHODS: Patients with at least 1 angiographically intermediate coronary lesion (50%-90% diameter stenosis) in a vessel ≥2.5 mm diameter were randomized to a QFR-guided (PCI performed only if QFR ≤0.80) or angiography-guided strategy. The primary endpoint was major adverse cardiac events (a composite of all-cause death, myocardial infarction, or ischemia-driven revascularization) at 1 year; 5-year outcomes data are reported herein. RESULTS: At 5 years, major adverse cardiac events composite was lower with QFR guidance than with angiography guidance (17.5% vs 21.1%; HR: 0.80; 95% CI: 0.69-0.92; P = 0.002), driven by fewer myocardial infarctions (5.8% vs 9.0%; HR: 0.63; 95% CI: 0.49-0.80; P < 0.0001) and ischemia-driven revascularizations (9.6% vs 12.0%; HR: 0.78; 95% CI: 0.64-0.95; P = 0.02) in the QFR-guided group. All-cause death did not differ between groups. Landmark analysis showed that the benefit of QFR guidance accrued predominantly within the first 2 years (8.5% vs 12.5%; HR: 0.66; 95% CI: 0.54-0.81; P < 0.0001), with similar outcomes between 2 and 5 years (10.2% vs 11.2%; HR: 0.90; 95% CI: 0.73-1.11; P = 0.32; P for interaction = 0.001). CONCLUSIONS: Compared with angiography guidance, QFR-guided strategy improved 5-year clinical outcomes, with benefits primarily achieved within the first 2 years. (The FAVOR III China Study; NCT03656848).
引用
- Zhang H, Guan C, Jin Z, et al. Angiographic Quantitative Flow Ratio-Guided Coronary Intervention: 5-Year Follow-Up From the FAVOR III China Randomized Trial. J Am Coll Cardiol. 2026. PMID: 42268156. doi:10.1016/j.jacc.2026.04.037
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。